Skip to main content
SpringerLink
Log in

Approach to the Patient with Hyperlipidemia

  • Chapter
Cardiology for the primary care Physician

  • 111 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

Key References

  • de Lorgeril M, Salen P, Martin J-L, et al.: Mediterranean diet, traditional risk factors and the rate of cardiovascular complications after myocardial infarction. Circulation 1999, 99:779–785.

    Google Scholar 

  • Pitt B, Waters D, Brown WV, et al.: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. NEnglJMed 1999, 341:70–76.

    Google Scholar 

  • Knopp RH: Drug treatment of lipid disorders. NEnglJMed 1999, 341: 498–511.

    Article  Google Scholar 

References and Recommended Reading

  1. Burke AP, Farb A, Malcolm GT, et al.: Coronary risk factors and plaque morphology in patients with coronary disease dying suddenly. NEnglJMed 1997, 336:1276–1282.

    Google Scholar 

  2. Brown BG, Zhao XQ,, Sacco DE, Albers JJ: Arteriographic view of treatment to achieve regression of coronary atherosclerosis and to prevent plaque disruption and clinical cardiovascular events. Br Heart J 1993, 69(suppl 1 ): S48 - S53.

    Google Scholar 

  3. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patient with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 269: 3015–3023.

    Google Scholar 

  4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. NEnglJ Med 1998, 339: 1349–1357.

    Article  Google Scholar 

  5. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. NEnglJMed 1996, 335:1001–1009.

    Google Scholar 

  6. Shepherd J, Cobbe SM, Ford I, et al.: for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N EnglJMed 1995, 333:1301–1307.

    Google Scholar 

  7. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Jama 1998, 279:1615–1622.

    Google Scholar 

  8. de Lorgeril M, Salen P, Martin J-L, et al.: Mediterranean diet, traditional risk factors and the rate of cardiovascular complications after myocardial infarction. Circulation 1999, 99:779–785.

    Google Scholar 

  9. Aviram M, Rosenblat M, Bisgaier CL, et al.: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paroxonase. J Clin Invest 1998, 101:1581–1590.

    Google Scholar 

  10. Cockerill GW, Saklatvala J, Ridley SH, et al.: High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2. Arterioscler Thromb Vase Biol

    Google Scholar 

  11. :910–917.

    Google Scholar 

  12. Saku K, Ahmad M, Glas-Greenwalt P, Kashyap ML: Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res 1985, 39: 1–8.

    Article  PubMed  CAS  Google Scholar 

  13. Rath M, Niendorf A, Reblin T, et al.: Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989, 9:579–592.

    Google Scholar 

  14. Maher VM, Brown BG, Marcovina SM, et al.: Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995, 274:1771–1774.

    Google Scholar 

  15. Lamon-Fava S, Wilson PW, SchaeferEJ: Impact on body mass index on coronary heart disease in men and women in the Framingham Offspring Study. Arteriosclerosis Thromb Vasc Bio11996, 16: 1509–1515.

    Google Scholar 

  16. O’Brien SF, Watts GF, Playford DA, et al.: Low-density lipoprotein size, high-density lipoprotein concentration, and endothelial dysfunction in non-insulin-dependent diabetes. Diabet Med 1997, 14:974–978.

    Google Scholar 

  17. Sacks FM, Ridker PM: Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Cholesterol and recurrent events. Herz 1999, 24: 51–56.

    Article  PubMed  CAS  Google Scholar 

  18. Ridker PM, Rifai N, Pfeffer MA, et al., for the Cholesterol and Recurrent Events (CARE) Investigators: Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999, 100: 230–235.

    Article  PubMed  CAS  Google Scholar 

  19. Ginsburg GS, Safran C, Pasternak RC: Frequency of low serum high density lipoprotein cholesterol levels in hospitalized patients with “desirable” total cholesterol levels. Am J Cardio11991, 68: 187–192.

    Google Scholar 

  20. Cooper GR, Myers GL, Smith J, Schlant RC: Blood lipid measurements. Variations and practical utility. JAMA 1992, 267: 1652–1660.

    Article  PubMed  CAS  Google Scholar 

  21. Gore JM, Goldberg RJ, Matsumoto AS, et al.: Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction. Am J Cardio11984,54:722–725.

    Google Scholar 

  22. Ryder REJ, Hayes TM, Mulligan IP, et al.: How soon after myocardial infarction should plasma lipid values be assessed? BMJ 1984, 289:65–63.

    Google Scholar 

  23. Avogaro P, Bon GB, Cazzolato G, et al.: Variations in apolipoproteins B and Al during the course of myocardial infarction. EurJClin Invest 1978, 8:121–129.

    Google Scholar 

  24. Kaplan NM: The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989, 149: 1514–1520.

    Article  PubMed  CAS  Google Scholar 

  25. Stamler J, Wentworth D, Neaton JD, et al.: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? JAMA 1986, 256:2823–2826.

    Google Scholar 

  26. Goldstein JL, Hazzard WR, Schrott HG, et al.: Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest 1973, 52:1533–1543.

    Google Scholar 

  27. Genest J, McNamara JR, Ordovas JM, et al.: Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary disease. JAm Coll Cardio11992,19:792–802.

    Google Scholar 

  28. Dayton S, Pearce ML, Hashimoto S, et al.: A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 1969, 40(suppl 2):2–1–2–63.

    Google Scholar 

  29. Hjermann I, Holme I, Leren P: Oslo study diet and antismoking trial results after 102 months. Am JMed 1986, 80 (suppl): 7–12.

    CAS  Google Scholar 

  30. Ornish D, Brown SE, Scherwitz LW, et al.: Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990, 336:129–133.

    Google Scholar 

  31. Watts GF, Lewis B, Brunt JNH, et al.: Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas Atherosclerosis Regression (STARS) Study. Lancet 1992, 339:563–569.

    Google Scholar 

  32. Burr ML, Fehily AM, Gilbert JF, et al.: Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989, 2:757–761.

    Google Scholar 

  33. de Lorgeril M, Renaud S, Mamelle N, et al.: Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994, 343:1454–1459.

    Google Scholar 

  34. de Lorgeril M, Salen P, Martin JL, et al.: Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999, 99:779–785.

    Google Scholar 

  35. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial GISSI-Prevenzione Investigators* (Gruppo Italian per lo Studio della Sopravvivenza nell’Infarto

    Google Scholar 

  36. miocardico). Lancet 1999, 354: 447–455.

    Article  Google Scholar 

  37. The Surgeon General’s Report on Nutrition and Health. U.S. Department of Health and Human Services. Public Health Service. USDHHS (PHS) Publication No. 88–50210, 1988.

    Google Scholar 

  38. Gorder DD, Dolecek TA, Coleman GG, et al.: Dietary intake in the Multiple Risk Factor Intervention Trial (MRFIT): nutrient and food group changes over 6 years. JAm Diet Assoc 1986, 86:744–751.

    Google Scholar 

  39. Klatsky AL, Armstrong MA, Friedman GD: Red wine, white wine, liquor, beer, and risk for coronary artery disease hospitalization. Am J Cardiol 1997, 80: 416–420.

    Article  PubMed  CAS  Google Scholar 

  40. Lichstenstein AH, Van Horn L: Very low fat diets. AHA science advisory. Circulation 1998, 98: 935–939.

    Article  Google Scholar 

  41. Stone NJ, Val Horn LV: Controlling cholesterol levels through diet. Postgrad Med 1988, 83: 229–242.

    PubMed  CAS  Google Scholar 

  42. Van Horn L: Fiber, lipids, and coronary heart disease. A statement for healthcare professionals from the nutrition committee, American Heart Association For the Nutrition Committee. Circulation 1997, 95: 2701–2704.

    Article  PubMed  Google Scholar 

  43. Hennekens CH, Buring JE, Manson JE, et al.: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. NEngl JMed 1996, 334:1145–1149.

    Google Scholar 

  44. Omenn GS, Goodman GE, Thornquist MD, et al.: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. NEngIJMed 1996, 334:1150–1155.

    Google Scholar 

  45. Cobb MM, Teitelbaum HS, Breslow JL: Lovastatin efficacy in reducing low-density lipoprotein cholesterol levels on high-vs low-fat diets. JAMA 1991, 265: 997–1001.

    Article  PubMed  CAS  Google Scholar 

  46. Wood PD, Stefanick ML, Williams PT, Haskell WL: The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. NEngl JMed 1991, 325: 461–466.

    Article  CAS  Google Scholar 

  47. Wood PD, Haskell WL, Blair SN, et al.: Increased exercise level and plasma lipoprotein concentrations: a one-year, randomized, controlled study in sedentary, middle-aged men. Metabolism 1983, 32:31–39.

    Google Scholar 

  48. Coleman KJ, Raynor HR, Mueller DM, et al: Providing sedentary adults with choices for meeting their walking goals. Prey Med 1999, 5: 510–519.

    Article  Google Scholar 

  49. Lichtman SW, Pisarska K, Berman ER, et al.: Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. NEngIJMed 1992, 327:1893–1898.

    Google Scholar 

  50. Walsh BW, Schiff I, Rosner B, et al.: Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma. NEngIJMed 1991, 325:1196–1204.

    Google Scholar 

  51. Hulley S, Grady D, Bush T, et al.,for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998, 280:605–613.

    Google Scholar 

  52. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial Result. I. Reduction in incidence of coronary heart disease. JAMA 1984, 251: 351–364.

    Article  Google Scholar 

  53. Frick MH, Eto O, Haapa K, et al.: Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. NEnglJMed 1987, 317:1237–1245.

    Google Scholar 

  54. Wilson PW, D’Agostino RB, Levy D, et al.: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837–1847.

    Google Scholar 

  55. LaRosa J, Cleeman JI: Cholesterol lowering as a treatment for established coronary heart disease. Circulation 1992, 85: 1229 1235.

    Google Scholar 

  56. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. NEngl JMed 1999, 341:410–418.

    Google Scholar 

  57. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al.: Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-Year follow-up. JAMA 1990, 264:3013–3017.

    Google Scholar 

  58. Brown G, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of interim lipid-lowering therapy in men with high levels of apolipoprotein B. NEngl JMed 1990, 323:1289–1298.

    Google Scholar 

  59. Kane JP, Malloy MJ, Ports TA, et al.: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990, 264:3007–3012.

    Google Scholar 

  60. Buchwald H, Varco RL, Matts JP, et al.: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. NEngIJMed 1990, 323:946–955.

    Google Scholar 

  61. The Post Coronary Artery Bypass Graft Trial Investigators: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. NEngIJMed 1997, 336: 153–162.

    Article  Google Scholar 

  62. Frick MH, Syvanne M, Nieminen MS, et al., for the Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997, 96: 2137–2143.

    Article  PubMed  CAS  Google Scholar 

  63. Pitt B, Waters D, Brown WV, et al: Aggressive lipid-lowering

    Google Scholar 

  64. therapy compared with angioplasty in stable coronary artery disease. NEngIJMed 1999, 341: 70–76.

    Article  Google Scholar 

  65. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998, 279: 1643–1650.

    Article  PubMed  CAS  Google Scholar 

  66. ^ Knopp RH: Drug treatment of lipid disorders. NEngIJMed 1999, 341: 498–511.

    Article  Google Scholar 

  67. Nawrocki JW, Weiss SR, Davidson MH, et al.: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Bio11995,15:678–682.

    Google Scholar 

  68. Muck W: Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs 1998, 56 (suppl 1): 15–23.

    Article  PubMed  CAS  Google Scholar 

  69. Knopp RH, Alagona P, Davidson M, et al.: Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998, 47:1097–1104.

    Google Scholar 

  70. Tato F, Vega GL, Grundy SM: Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardio11998,81(6):805–807.

    Google Scholar 

  71. Stone NJ: Fish consumption, fish oil, lipids, and coronary heart disease. Circulation 1996, 94: 2337–2340.

    Article  PubMed  CAS  Google Scholar 

  72. Vega GL, Grundy SM: Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men. Am J Cardiol1998, 81: 36B - 42B.

    Google Scholar 

  73. Zambon D, Ros E, Rodriguez-Villar C, et al.: Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation. Metabolism 1999, 48:47–54.

    Google Scholar 

  74. Ballantyne CM, Herd JA, Ferlic LL, et al.: Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999, 99:736–743.

    Google Scholar 

  75. Badimon JJ, Fuster V, Chesebro JH, Badimon L: Coronary atherosclerosis. A multifactorial disease. Circulation 1993, 87(suppl 2):2–3–2–16.

    Google Scholar 

Download references

Authors
  1. Neil J. Stone
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, University of Arizona, Health Sciences Center, Tucson, Arizona, USA

    Joseph S. Alpert MD (Professor and Chairman, Professor of Medicine, Head) (Professor and Chairman, Professor of Medicine, Head)

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Current Medicine, Inc.

About this chapter

Cite this chapter

Stone, N.J. (2001). Approach to the Patient with Hyperlipidemia. In: Alpert, J.S. (eds) Cardiology for the primary care Physician. Current Medicine Group. https://doi.org/10.1007/978-1-4615-6601-4_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-6601-4_14

  • Publisher Name: Current Medicine Group

  • Print ISBN: 978-1-4615-6603-8

  • Online ISBN: 978-1-4615-6601-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation